PU files patents for green nanoplatform in skincare and pharma

Chandigarh: Panjab University has filed Indian and international patents for a new green nanomicelle platform developed by Professor Indu Pal Kaur and her PhD scholars Bakr Ahmed and Simrandeep Kaur.

The solvent-free, eco-friendly technology enables targeted delivery of sensitive bioactives such as peptides, herbal extracts, cannabinoids, vitamins, proteins, and small molecules.These components have applications in pharmaceuticals, nutraceuticals, cosmetics, paediatrics, veterinary care, and wellness products.

The platform is scalable and designed for clean-label processes, with formulations developed at room temperature. Minimal use of USFDA-approved solvents is allowed to accommodate poorly soluble actives without compromising safety or scalability. The technology has already been transferred to an industrial partner for skincare and cosmetics applications, marking a key step in academia-industry collaboration.

Professor Indu Pal Kaur, who leads the IPK Lab at Panjab University, described the innovation as affordable and adaptable, supporting both MSMEs and global companies in developing safe and sustainable products. Her lab focuses on turning research challenges into practical solutions, with a strong emphasis on long-term partnerships and technology transfer.
The university’s Centre for Industry-Institute Partnership Programme, established in 1996, plays a vital role in fostering innovation through revenue-sharing models between faculty and the institution.

Panjab University vice-chancellor Renu Vig said the university takes pride in translating research into industry-relevant innovations that improve lives and enhance its academic reputation.
With more than 22 patents granted and 17 filed, Professor Kaur’s work highlights the growing importance of intellectual property in India’s innovation ecosystem.

Related Posts

AstraZeneca, NIPER Raebareli partner to upgrade 25 clinical trail sites

New Delhi: AstraZeneca’s India-arm has partnered with National Institute of Pharmaceutical Education and Research (NIPER), Raebareli, to build clinical research capabilities at 25 emerging geographies in a bid to extend…

FDA clears ImmunityBio’s Anktiva expansion in bladder cancer after regulatory whiplash

Following a bumpy regulatory road that involved a refusal-to-file, ImmunityBio has won FDA approval to expand Anktiva into papillary-only non-muscle-invasive bladder cancer (NMIBC). Wednesday’s approval comes nearly three months ahead…

Leave a Reply

Your email address will not be published. Required fields are marked *

You Missed

AstraZeneca, NIPER Raebareli partner to upgrade 25 clinical trail sites

AstraZeneca, NIPER Raebareli partner to upgrade 25 clinical trail sites

FDA clears ImmunityBio’s Anktiva expansion in bladder cancer after regulatory whiplash

FDA clears ImmunityBio’s Anktiva expansion in bladder cancer after regulatory whiplash

Sun Pharma Approves Rs 10,000 Crore Fundraising Through NCDs

Sun Pharma Approves Rs 10,000 Crore Fundraising Through NCDs

‘Bone Bonding’ between Mothers and Children, thanks to Meticulous Bone Grafting

‘Bone Bonding’ between Mothers and Children, thanks to Meticulous Bone Grafting

Governments have moved for Price Transparency in Hospitals to help patients cope with bills

Governments have moved for Price Transparency in Hospitals to help patients cope with bills

The Most Innovative Medical Devices of 2026: Breakthrough Technologies Target Heart Disease, Cancer, Neurological Disorders and Kidney Dysfunction

The Most Innovative Medical Devices of 2026: Breakthrough Technologies Target Heart Disease, Cancer, Neurological Disorders and Kidney Dysfunction